Medtronic Jewel AF ICD Approvable With Conditions, FDA Panel Says
This article was originally published in The Gray Sheet
Executive Summary
Medtronic expects FDA approval of its Jewel AF dual chamber implantable cardioverter defibrillator by the end of the year following a unanimous (4-0) approval with conditions recommendation June 24 from the agency's Circulatory System Devices Panel.
You may also be interested in...
Jewel AF ICD Atrial Fib Detection Sensitivity/Specificity Tops 99%
Medtronic's Jewel AF dual-chamber implantable cardioverter defibrillator (ICD) continuously detects sustained atrial fibrillation (AF) and atrial flutter (AFl) with over 99% sensitivity/specificity and can be programmed for long duration AF without the risk of underdetection, Charles Swerdlow, MD, Cedars-Sinai Medical Center, Los Angeles, reported Nov. 8 at the American Heart Association's annual scientific sessions in Atlanta.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.